Saxagliptin — Discount Pricing

Other medications in Diabetes & Metabolism

• Semaglutide
• Semaglutide (Obesity)
• Sitagliptin
• Tirzepatide
• Tolvaptan
• Acarbose
• Alogliptin
• Burosumab

About Saxagliptin

Saxagliptin is a medication prescribed to help adults with Type 2 Diabetes manage their blood sugar levels, often used alongside diet and exercise. Understanding your treatment options and their costs is crucial. TheDrugClub is dedicated to helping our members access significant savings on essential prescriptions like saxagliptin, making your healthcare more affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Saxagliptin is approved for (FDA label)

Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Limitations of use: • Not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 ) 1.1 Monotherapy and Combination Therapy Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [ see Clinical Studies ( 14 ) ]. 1.2 Limitation of Use Saxagliptin tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. 1.1 Monotherapy and Combination Therapy Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [ see Clinical Studies ( 14 ) ].

Source: Read the full FDA label on DailyMed. Label effective date: January 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Saxagliptin (FDA label)

• 2.5 mg: pale yellow to yellow, biconvex, round, film-coated tablets with “G74” printed on one side, in blue ink. • 5 mg: pink, biconvex, round, film-coated tablets with “G75” printed on one side, in blue ink • Tablets: 5 mg and 2.5 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: e286ffd4-c598-47fb-af06-2e15f7e6f99f. SPL document ID: 4d1a25c6-4ffc-4714-98a9-c4dcb2049d6d. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Saxagliptin (FDA label)

The following serious adverse reactions are described below or elsewhere in the prescribing information: • Pancreatitis [ see Warnings and Precautions (5.1) ] • Heart Failure [ see Warnings and Precautions (5.2) ] • Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues [ see Warnings and Precautions ( 5.3 ) ] • Hypersensitivity Reactions [ see Warnings and Precautions ( 5.4 ) ] • Severe and disabling arthralgia [ see Warnings and Precautions (5.5) ] • Bullous pemphigoid [ see Warnings and Precautions (5.6) ] • Most common adverse reactions (incidence ≥ 5% and more often than placebo) are upper respiratory tract infection, urinary tract infection, and headache. ( 6.1 ) • Peripheral edema was reported more commonly in patients treated with the combination of saxagliptin and a thiazolidinedione (TZD) than in patients treated with the combination of placebo and TZD. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: e286ffd4-c598-47fb-af06-2e15f7e6f99f. SPL document ID: 4d1a25c6-4ffc-4714-98a9-c4dcb2049d6d. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Saxagliptin (FDA label)

Saxagliptin tablets are contraindicated in patients with a history of a serious hypersensitivity reaction to saxagliptin or any of the ingredients in saxagliptin tablets. Reactions such as anaphylaxis, angioedema, or exfoliative skin conditions have been reported with saxagliptin tablets [ see Warnings and Precautions ( 5.4 ) and Adverse Reactions (6.2) ]. • History of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to saxagliptin or any of the ingredients in saxagliptin. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: e286ffd4-c598-47fb-af06-2e15f7e6f99f. SPL document ID: 4d1a25c6-4ffc-4714-98a9-c4dcb2049d6d. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Saxagliptin (FDA label)

• Pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue saxagliptin. ( 5.1 ) • Heart Failure: Consider the risks and benefits of saxagliptin in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. ( 5.2 ) • Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues: Consider a lower dosage of insulin or insulin secretagogue when used in combination wtih Saxagliptin tablets ( 5.3 ) • Hypersensitivity-Related Events There have been postmarketing reports of serious hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions. If hypersensitivity reactions occur, discontinue saxagliptin, treat promptly, and monitor until signs and symptoms resolve. ( 5.4 ) • Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.

Source: FDA prescribing information (DailyMed). Set ID: e286ffd4-c598-47fb-af06-2e15f7e6f99f. SPL document ID: 4d1a25c6-4ffc-4714-98a9-c4dcb2049d6d. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Saxagliptin (FDA label)

• Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin significantly increases saxagliptin concentrations. Limit saxagliptin dosage to 2.5 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. ( 7.1 ) 7.1 Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. Similar significant increases in plasma concentrations of saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). The dosage of saxagliptin should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor [ see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ]. 7.2 Insulin or Insulin Secretagogues Insulin and insulin secretagogues are known to cause hypoglycemia. Concomitant use of saxagliptin tablets with insulin or an insulin secretagogue may require lower dosages of insulin or the insulin secretagogue to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].

Source: FDA prescribing information (DailyMed). Set ID: e286ffd4-c598-47fb-af06-2e15f7e6f99f. SPL document ID: 4d1a25c6-4ffc-4714-98a9-c4dcb2049d6d. Label effective date: January 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.